Today’s Actionable Stocks: Raytheon Company (RTN), Allergan plc (AGN) – The RNS Daily

This post was originally published on this site

Raytheon Company (NYSE:RTN) rose 0.62% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -17.68% and is now up by 19.18% since start of this year. A look at its monthly performance shows that the stock has recorded a 2.7% gain over the past 30 days. Its equity price climbed by 13.86% over the past three months which led to its overall six-month decrease to stand at -4.31%.

The shares of Raytheon Company (RTN) dropped by -20.45% or -$46.99 from its last recorded high of $229.75 which it attained on April 24 to close at $182.76 per share. Over the past 52 weeks, the shares of Raytheon Company has been trading as low as $144.27 before witnessing a massive surge by 26.68% or $38.49. This price movement has led to the RTN stock receiving more attention and has become one to watch out for. It dipped by -0.89% on Monday and this got the market worried. The stock’s beta now stands at 0.99 and when compared to its 200-day moving average and its 50-day moving average, RTN price stands -0.79% below and 0.97% above respectively. Its average daily volatility for this week is 1.3% which is less than the 1.6% recorded over the past month.

Experts from research firms are bullish about the near-term performance of Raytheon Company with most of them predicting a $205.76 price target on a short-term (12 months) basis. The average price target by the analysts will see a 12.58% rise in the stock and would lead to RTN’s market cap to surge to $58.52B. The stock has been rated an average 1.8, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 20 analysts that track Raytheon Company (NYSE:RTN) and find out that 6 of them rated it as a Hold. 14 of the 14 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

A look at RTN technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 53.58 point. Its trading volume has lost -846379 shares compared to readings over the past three months as it recently exchanged 1143621 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 1990000 shares, and this is 0.57 times the normal volume.

The price of Allergan plc (NYSE:AGN) currently stands at $143.58 after it went down by $-1.37 or -0.95% and has found a strong support at $142.55 a share. If the AGN price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $141.51 mark would also be bad for the stock as it means that the stock would plunge by 1.44% from its current position. However, if the stock price is able to trade above the resistance point around $144.74, then it could likely surge higher to try and break the upward resistance which stands at $145.89 a share. Its average daily volatility over the past one month stands at 1.85%. The stock has plunged by 0.63% from its 52-weeks high of $142.67 which it reached on Mar. 10, 2018. In general, it is 12.36% above its 52-weeks lowest point which stands at $125.84 and this setback was observed on Dec. 26, 2018.

Analysts have predicted a price target for Allergan plc (AGN) for 1 year and it stands at an average $186.95/share. This means that it would likely increase by 30.21% from its current position. The current price of the stock has been moving between $142.67 and $144.86. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $153. On the other hand, one analyst is super bullish about the price, setting a target as high as $255.

The AGN stock Stochastic Oscillator (%D) is at 16.1%, which means that it is currently oversold and its prices could jump very soon. The shares P/S ratio stands at 3.02 which compares to the 6.99 recorded by the industry or the 9 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 8.24, which is higher than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -36% over the past five years.

Analysts view Allergan plc (NYSE:AGN) as a Hold, with 2.1 consensus rating. Reuters surveyed 22 analysts that follow AGN and found that 9 of those analysts rated the stock as a Hold. The remaining 13 were divided, with 13 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Allergan plc (AGN) shares or sell it if they already own it.

This post was originally published on *this site*